StockNews.com Upgrades Voyager Therapeutics (NASDAQ:VYGR) to “Buy”

StockNews.com upgraded shares of Voyager Therapeutics (NASDAQ:VYGR) from a hold rating to a buy rating in a report issued on Monday.

Several other equities research analysts also recently issued reports on the stock. Canaccord Genuity Group reissued a “buy” rating and set a $14.00 price objective on shares of Voyager Therapeutics in a research report on Thursday, November 14th. Leerink Partners started coverage on Voyager Therapeutics in a report on Wednesday, October 16th. They set an “outperform” rating and a $15.00 target price for the company. Wedbush cut their price target on Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating on the stock in a report on Wednesday, August 7th. Leerink Partnrs upgraded Voyager Therapeutics to a “strong-buy” rating in a report on Wednesday, October 16th. Finally, HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of Voyager Therapeutics in a research report on Thursday, November 14th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Voyager Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $17.00.

Voyager Therapeutics Trading Up 1.3 %

Shares of Voyager Therapeutics stock opened at $5.43 on Monday. The stock’s fifty day simple moving average is $6.57 and its 200 day simple moving average is $7.43. The company has a market capitalization of $296.64 million, a PE ratio of 7.65 and a beta of 0.89. Voyager Therapeutics has a 12 month low of $5.19 and a 12 month high of $11.72.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.29. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The company had revenue of $24.63 million for the quarter, compared to analyst estimates of $12.63 million. During the same quarter last year, the firm posted ($0.59) earnings per share. Analysts predict that Voyager Therapeutics will post -1.03 EPS for the current fiscal year.

Insider Activity

In other news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total value of $34,914.18. Following the sale, the insider now directly owns 86,001 shares of the company’s stock, valued at approximately $500,525.82. This represents a 6.52 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.53% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Voyager Therapeutics

Institutional investors have recently bought and sold shares of the business. Great Point Partners LLC acquired a new position in shares of Voyager Therapeutics during the 2nd quarter worth approximately $12,668,000. Erste Asset Management GmbH acquired a new stake in shares of Voyager Therapeutics during the 3rd quarter worth about $6,192,000. Farallon Capital Management LLC grew its stake in Voyager Therapeutics by 77.4% in the 1st quarter. Farallon Capital Management LLC now owns 2,292,000 shares of the company’s stock valued at $21,339,000 after buying an additional 1,000,000 shares during the last quarter. Vanguard Group Inc. grew its stake in Voyager Therapeutics by 27.8% in the 1st quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company’s stock valued at $30,087,000 after buying an additional 702,030 shares during the last quarter. Finally, Armistice Capital LLC grew its stake in Voyager Therapeutics by 11.3% in the 2nd quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock valued at $41,132,000 after buying an additional 528,000 shares during the last quarter. Institutional investors and hedge funds own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.